-
Something wrong with this record ?
The Brussels International Declaration on Lipoprotein(a) Testing and Management
F. Kronenberg, N. Bedlington, Z. Ademi, M. Geantă, T. Silberzahn, M. Rijken, A. Kaal, M. Harada-Shiba, Z. Chen, G. Thanassoulis, B. Eliasen, JL. Eiselé, A. Wiegman, CM. Ballantyne, E. Broome, M. Calabrò, P. Corral, A. Dol, LJ. Donato, E. Evans,...
Language English Country Ireland
Document type Journal Article
- MeSH
- Biomarkers blood MeSH
- Risk Assessment MeSH
- Cardiovascular Diseases * blood diagnosis prevention & control epidemiology MeSH
- Consensus MeSH
- Humans MeSH
- Lipoprotein(a) * blood MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations. The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union. The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.
Cardiovascular Center Osaka Medical and Pharmaceutical University Osaka Japan
Center for Innovation in Medicine Bucharest Romania
Center for Lipid Metabolomics Brigham and Women's Hospital Harvard Medical School Boston MA USA
Centre for Health and Technology University of South Eastern Norway Norway
Department of Cardiovascular Medicine Kyorin University Faculty of Medicine Mitaka Japan
Department of Clinical Biochemistry Copenhagen University Hospital Herlev and Gentofte Denmark
Department of Internal Medicine and Pediatrics Ghent University Hospital Ghent Belgium
Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA
Department of Public Health and Primary Care Imperial College London London UK
European Regional and Local Health Authorities Brussels Belgium
FASTA University School of Medicine Pharmacology and Research Department Mar Del Plata Argentina
FH Europe Foundation Amsterdam Netherlands
Global Heart Hub Galway Ireland
Hospital Israelita Albert Einstein and University of Sao Paulo Brazil
Institute of Genetic Epidemiology Medical University of Innsbruck Innsbruck Austria
Institute of Science Tokyo Depatment of Medical Genetics Tokyo Japan
International Atherosclerosis Society Washington DC USA
Lp International Task Force FH Europe Foundation Amsterdam Netherlands
Monash University Victoria Heart Institute Melbourne Australia
Movement Health Foundation Switzerland
Preventive and Genomic Cardiology McGill University Health Center Montréal Québec Canada
Stichting Health Clusternet Amsterdam Netherlands
The Copenhagen General Population Study Copenhagen University Hospital Herlev and Gentofte Denmark
World Heart Federation Geneva Switzerland
Zagreb School of Medicine University of Zagreb University Hospital Center Zagreb Zagreb Croatia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015190
- 003
- CZ-PrNML
- 005
- 20250731090820.0
- 007
- ta
- 008
- 250708e20250505ie f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.atherosclerosis.2025.119218 $2 doi
- 035 __
- $a (PubMed)40340180
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Kronenberg, Florian $u Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria; Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands. Electronic address: Florian.Kronenberg@i-med.ac.at
- 245 14
- $a The Brussels International Declaration on Lipoprotein(a) Testing and Management / $c F. Kronenberg, N. Bedlington, Z. Ademi, M. Geantă, T. Silberzahn, M. Rijken, A. Kaal, M. Harada-Shiba, Z. Chen, G. Thanassoulis, B. Eliasen, JL. Eiselé, A. Wiegman, CM. Ballantyne, E. Broome, M. Calabrò, P. Corral, A. Dol, LJ. Donato, E. Evans, S. Funabashi, I. Gouni-Berthold, IG. Ibarluzea, N. Johnson, J. Lane, S. Mora, BG. Nordestgaard, I. Pećin, R. Kaal-Poppelaars, MR. Langlois, KK. Ray, A. Rodenbach, RD. Santos, ESG. Stroes, H. Tada, M. Vrablík, M. Winokur, M. Yoshida, SJ. Nicholls, M. Daccord
- 520 9_
- $a There is striking evidence that a high lipoprotein(a) [Lp(a)] concentration is a strong, independent, and causal cardiovascular risk factor. However, Lp(a) testing rates are very low (1 %-2 %) despite the fact that 1 in 5 individuals have elevated Lp(a) concentrations. The Brussels International Declaration on Lp(a) Testing and Management was co-created by the Lp(a) International Task Force and global leaders at the Lp(a) Global Summit, held in Brussels, Belgium, on March 24-25, 2025. The event, organized by FH Europe Foundation, brought together scientific experts, people with the lived experience of elevated Lp(a) and policy makers from the European Institutions and World Health Organization. The World Heart Federation, Global Heart Hub, and European Alliance for Cardiovascular Health and scientific organizations such as European Atherosclerosis Society, and International Atherosclerosis Society were formal partners. The Summit was hosted by a Member of the European Parliament, Romana Jerković, and held under the patronage of the Polish presidency of the Council of the European Union. The Declaration calls for 1) integration of Lp(a) testing and management into Global, European and National Cardiovascular Health Plans; 2) appropriate investment, policy and programmes in targeting Lp(a) testing and management based on a recent study demonstrating the substantial overall cost-saving to health systems across the globe; 3) political commitment to mandate systematic Lp(a) testing at least once during a person's lifetime, ideally at an early age, with full reimbursement; 4) incorporation of Lp(a) test results in the context of a person's cardiovascular risk assessment, with development of personalised cardiovascular health roadmaps as needed, without fear of dredit aiscrimination; 5) investment in public and healthcare professional education to increase awareness of Lp(a) and its impact on cardiovascular health.
- 650 12
- $a lipoprotein (a) $x krev $7 D017270
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a kardiovaskulární nemoci $x krev $x diagnóza $x prevence a kontrola $x epidemiologie $7 D002318
- 650 _2
- $a biologické markery $x krev $7 D015415
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a konsensus $7 D032921
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bedlington, Nicola $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Ademi, Zanfina $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Health Economics and Policy Evaluation Research (HEPER) Group, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia
- 700 1_
- $a Geantă, Marius $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Center for Innovation in Medicine, Bucharest, Romania
- 700 1_
- $a Silberzahn, Tobias $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Rijken, Marc $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Kaal, Aedan $u FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Harada-Shiba, Mariko $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Cardiovascular Center, Osaka Medical and Pharmaceutical University, Osaka, Japan
- 700 1_
- $a Chen, Zhenyue $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 700 1_
- $a Thanassoulis, George $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Preventive and Genomic Cardiology, McGill University Health Center, Montréal, Québec, Canada
- 700 1_
- $a Eliasen, Bogi $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Movement Health Foundation, Switzerland
- 700 1_
- $a Eiselé, Jean-Luc $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; World Heart Federation (WHF), Geneva, Switzerland
- 700 1_
- $a Wiegman, Albert $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; Department of Pediatrics Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Ballantyne, Christie M $u Sections of Cardiology and Cardiovascular Research, Department of Medicine, Baylor College of Medicine and the Texas Heart Institute, Houston, TX, USA
- 700 1_
- $a Broome, Emma $u FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Calabrò, Michele $u European Regional and Local Health Authorities, Brussels, Belgium
- 700 1_
- $a Corral, Pablo $u FASTA University, School of Medicine, Pharmacology and Research Department, Mar Del Plata, Argentina
- 700 1_
- $a Dol, Annelies $u FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Donato, Leslie J $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
- 700 1_
- $a Evans, Elsie $u FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Funabashi, Sayaka $u Department of Cardiovascular Medicine, Kyorin University, Faculty of Medicine, Mitaka, Japan
- 700 1_
- $a Gouni-Berthold, Ioanna $u Center for Endocrinology, Diabetes and Preventive Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- 700 1_
- $a Ibarluzea, Iñaki Gutierrez $u Stichting Health Clusternet, Amsterdam, Netherlands
- 700 1_
- $a Johnson, Neil $u Global Heart Hub, Galway, Ireland
- 700 1_
- $a Lane, Joanna $u FH Europe Foundation, Amsterdam, Netherlands; Stichting Health Clusternet, Amsterdam, Netherlands; Centre for Health and Technology, University of South-Eastern Norway, Norway
- 700 1_
- $a Mora, Samia $u International Atherosclerosis Society, Washington, DC, USA; Center for Lipid Metabolomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Nordestgaard, Børge G $u Department of Clinical Biochemistry, Copenhagen University Hospital - Herlev and Gentofte, Denmark; The Copenhagen General Population Study, Copenhagen University Hospital - Herlev and Gentofte, Denmark; Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- 700 1_
- $a Pećin, Ivan $u Zagreb School of Medicine, University of Zagreb, University Hospital Center Zagreb, Zagreb, Croatia
- 700 1_
- $a Kaal-Poppelaars, Renate $u FH Europe Foundation, Amsterdam, Netherlands
- 700 1_
- $a Langlois, Michel R $u EFLM (European Federation of Clinical Chemistry and Laboratory Medicine), Brussels, Belgium
- 700 1_
- $a Ray, Kausik K $u Department of Public Health and Primary Care, Imperial College London, London, UK
- 700 1_
- $a Rodenbach, Arthur $u Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium
- 700 1_
- $a Santos, Raul D $u Hospital Israelita Albert Einstein and University of Sao Paulo, Brazil
- 700 1_
- $a Stroes, Erik S G $u Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands
- 700 1_
- $a Tada, Hayato $u Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan
- 700 1_
- $a Vrablík, Michal $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic
- 700 1_
- $a Winokur, Michelle $u International Atherosclerosis Society, Washington, DC, USA
- 700 1_
- $a Yoshida, Masayuki $u Institute of Science Tokyo, Depatment of Medical Genetics, Tokyo, Japan
- 700 1_
- $a Nicholls, Stephen J $u Monash University Victoria Heart Institute, Melbourne, Australia
- 700 1_
- $a Daccord, Magdalena $u Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands; FH Europe Foundation, Amsterdam, Netherlands. Electronic address: md@fheurope.org
- 773 0_
- $w MED00009284 $t Atherosclerosis $x 1879-1484 $g Roč. 406 (20250505), s. 119218
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40340180 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731090814 $b ABA008
- 999 __
- $a ok $b bmc $g 2366193 $s 1252315
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 406 $c - $d 119218 $e 20250505 $i 1879-1484 $m Atherosclerosis $n Atherosclerosis $x MED00009284
- LZP __
- $a Pubmed-20250708
